Renal Insufficiency and Renal Artery Occlusive Disease


Until the early 1960s, the pathophysiology and management of atherosclerotic renovascular disease focused solely on hypertension. However, current management of renal artery atherosclerosis considers the relationship between renal artery occlusive disease and renal insufficiency, a relationship recognized by the term ischemic nephropathy. In 1962, Morris and associates reported on eight azotemic patients with global renal ischemia who had improved blood pressure and kidney function after renal revascularization. Subsequently, Dean, Libertino, and Novick and their groups demonstrated beneficial function response after surgical correction of bilateral renal artery lesions. Despite a growing enthusiasm for correction of atherosclerotic renovascular disease to improve excretory kidney function, critical questions of patient selection and best management remain unanswered.

Pathophysiology

The pathophysiology of ischemic nephropathy remains incompletely understood. The earliest clinical reports suggested a glomerular filtration failure based on decreased perfusion pressure within the kidney; however, the cellular and subcellular basis for ischemic nephropathy is poorly defined. Like renovascular hypertension, the renin–angiotensin system likely contributes to ischemic nephropathy through its paracrine effects, with intrarenal angiotensin peptides affecting arteriolar tone. Angiotensin peptides have also been shown to promote tubular injury and interstitial fibrosis in the presence of atherosclerotic renal artery stenosis. This observation is supported by an increase in interstitial platelet-derived growth factor β, which is associated with increased extracellular matrix and interstitial fibrosis.

In addition to these possible contributors to excretory renal insufficiency, an atherosclerotic lesion may also contribute to an irreversible loss of kidney function as a source of atheroemboli. Unfortunately, studies that distinguish potentially reversible ischemic nephropathy from irreversible renal parenchymal disease are lacking. This distinction is of significant clinical importance because recovery of kidney function after correction of atherosclerotic kidney lesions associated with ischemic nephropathy has proved to be the single strongest predictor of dialysis-free survival on follow-up.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here